These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11526725)

  • 1. [Treatment of ovarian carcinoma with intraperitoneal administration of interferon alpha 2b].
    Ambrosio D; Piscopo L; Lauro C; Rotondi M; Gallo E; Balbi F
    Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):67-71. PubMed ID: 11526725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 2b interferon (IFN) by intraperitoneal administration via temporary catheter in ovarian cancer. Preliminary data.
    Iaffaioli RV; Frasci G; Facchini G; Pagliarulo C; Pacelli R; Scala S; Espinosa A; Bianco AR
    Eur J Gynaecol Oncol; 1991; 12(1):69-75. PubMed ID: 2050163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
    Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P
    Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer.
    Bezwoda WR; Seymour L; Dansey R
    Cancer; 1989 Sep; 64(5):1029-33. PubMed ID: 2758381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer.
    Mäenpää J; Kivinen S; Räisänen I; Sipilä P; Väyrynen M; Gröhn P
    Ann Chir Gynaecol Suppl; 1994; 208():25-7. PubMed ID: 8092765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.
    Sartori S; Nielsen I; Tassinari D; Trevisani L; Abbasciano V; Malacarne P
    Oncology; 2001; 61(3):192-6. PubMed ID: 11574774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
    Alberts DS; Hannigan EV; Liu PY; Jiang C; Wilczynski S; Copeland L; Markman M
    Gynecol Oncol; 2006 Jan; 100(1):133-8. PubMed ID: 16153694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal therapy in the management of patients with ovarian cancer.
    McClay EF; Howell SB
    Hematol Oncol Clin North Am; 1992 Aug; 6(4):915-26. PubMed ID: 1500393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron
    Green DS; Nunes AT; David-Ocampo V; Ekwede IB; Houston ND; Highfill SL; Khuu H; Stroncek DF; Steinberg SM; Zoon KC; Annunziata CM
    J Transl Med; 2018 Jul; 16(1):196. PubMed ID: 30012146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.
    Repetto L; Chiara S; Guido T; Bruzzone M; Oliva C; Ragni N; Conte PF; Rosso R
    Anticancer Res; 1991; 11(4):1641-3. PubMed ID: 1746921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer].
    Cheng A; Peng Z; Hong Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1999 Mar; 30(1):95-8. PubMed ID: 12205938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease].
    Cherchi PL; Dessole S; Esposito F; Ambrosini G; El Qandil FZ; Ambrosini A
    J Gynecol Obstet Biol Reprod (Paris); 1996; 25(1):101-2. PubMed ID: 8901311
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained-release protamine sulphate-impregnated microspheres may reduce the frequent administration of recombinant interferon α-2b in ovarian cancer: in-vitro characterization.
    Gulia M; Rai S; Jain UK; Katare OP; Katyal A; Madan J
    Anticancer Drugs; 2014 Jan; 25(1):63-71. PubMed ID: 24052106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala MK; Alagarsamy S; McGuire WP
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical immunotherapy for superficial bladder cancer.
    Said MT; Abomelha MS; Orkubi SA
    Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
    O'Donnell MA; Krohn J; DeWolf WC
    J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intraperitoneal chemotherapy in ovarian carcinoma].
    Piura B
    Harefuah; 2001 Sep; 140(9):844-9, 894, 893. PubMed ID: 11579736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.